Experimental brain cancer therapy seeks to control deadly tumor growth
NCT ID NCT06102525
Summary
This early-stage trial is testing whether a new drug called RZ-001, when combined with an existing antiviral medication (valganciclovir), can help control glioblastoma, an aggressive brain cancer. The study will first determine safe doses and then see if the treatment shows signs of slowing tumor growth and extending survival. It's enrolling 43 adults with specific types of glioblastoma who have already been diagnosed.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asan Medical Center
RECRUITINGSeoul, 05505, South Korea
Contact
-
Gachon University Gil Medical Center
RECRUITINGIncheon, 21565, South Korea
Contact
-
Samsung Medical Center
RECRUITINGSeoul, 06351, South Korea
Contact
-
Seoul National University Bundang Hospital
RECRUITINGSeongnam-si, 13620, South Korea
Contact
-
Severance Hospital, Yonsei University Health System
RECRUITINGSeoul, 03722, South Korea
Contact
-
The Catholic University of Korea, Incheon St. Mary's Hospital
RECRUITINGIncheon, 21431, South Korea
Contact
Conditions
Explore the condition pages connected to this study.